766.21

PATENT APPLICATION DIVI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DEC 1 4 1999

RECEIVED

In re Application of:

GENES

Examiner: N/Y/A

TECH CENTER 1600/2900

TETSUYOSHI ISHIWATA et al. RANG

Group Art Unit: 1643

RECEIVED

Application No.: 09/090,672
Filed: June 4, 1998

UEU 2 1 1999

For: IGA NEPHROPATHY-RELATED

December 13, 1999

**TECH CENTER 1600/2900** 

Assistant Commissioner for Patents Washington, D.C. 20231

## SECOND SUBMISSION OF COMPUTER READABLE FORM

Sir:

Applicants herewith respond to the Office Action dated November 15, 1999 (Paper No. 6). The Official Action included a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence Disclosures ("Notice to Comply") and accompanying CRF Diskette Problem Report. The Notice to Comply stated that the CRF was damaged and/or unreadable. A copy of the Notice to Comply is enclosed.

However, it is understood that the CRF actually was neither damaged nor unreadable, since the Office Action also included a marked-up copy showing that the Sequence

Box

Listing was improperly formatted, e.g., as not conforming with 37 C.F.R. §§1.822 and/or 1.823.

Accordingly, in response, Applicants undersigned attorney has reformatted the CRF so as to conform with the requirements of the C.F.R. A copy of the CRF in ASCII (DOS) text is enclosed, together with a replacement paper copy to be substituted for the paper copy of record. The contents of the enclosed paper copy is the same as that of the CRF; moreover, neither the reformatted CRF nor the replacement paper copy add any new matter to the application.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

Attorney for Applicants

Lawrence S. Perry

Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO 30 Rockefeller Plaza New York, New York 10112-3801 Facsimile: (212) 218-2200

LSP\ac

NY\_MAIN 47411 v 1

Application No.: 09/090,672

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

comply wi	otide and/or amino acid sequence disclosure contained in this application does not the requirements for such a disclosure as sectorth in 37 C.F.R. 1.821 - 1.825 for the reason(s):  \[ \begin{align*} \text{DEC 1 4 1999 & 3 \\ 0 & 1 & 1999 & 3 \\ 0 & 1 & 1 & 1999 & 3 \\ 0 & 1 & 1 & 1 & 1 & 1 \end{align*} \]
	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
×	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Ap	plicant Must Provide:
X	An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".
	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Fo	r questions regarding compliance to these requirements, please contact:
Fo	r Rules Interpretation, call (703) 308-4216

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

For CRF Submission Help, call (703) 308-4212 For Patentin software help, call (703) 308-6856